- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03831256
Personliggjort genomik til screening af prænatale abnormiteter ved hjælp af moderblod (PEGASUS-2)
Personliggjort genomik for screening af prænatale abnormiteter ved brug af moderblod: Mod første niveausscreening og videre
This project aims to provide high- quality evidence to inform decisions by health care organisations about using first-tier non-invasive prenatal screening (NIPS) to replace traditional screening tests for trisomy 21, and potentially to screen for other fetal chromosome anomalies. We will compare the current screening approach of second-tier NIPS with the use of first-tier NIPS in a large cohort of pregnant women.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
There is some data on the performance of NIPS as a first tier screening test but our systematic review has shown that no trial comparing the effectiveness (utility) of 2nd-tier NIPS with that of first-tier NIPS has been published . Further it is important for health care decision makers to have evidence produced in Canada since the geographical context of healthcare can affect uptake as well as patient decision and thus their healthcare trajectories. There is a need for a trial that is between an explanatory trial and a pragmatic trial to provide the types of answer that we aim to document in the present state of knowledge on NIPS-based screening strategies in Canada. Our Objective is to perform a pan-Canadian large-scale comparative utility (clinical outcomes) study of first-tier NIPS (expanded or not) as compared to the new standard of care (NIPS as a 2nd tier test performed much later during pregnancy and only in high risk pregnancies).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 1P2
- Kelowna Regional Fertility Center
-
Prince Rupert, British Columbia, Canada, V8J 2A6
- Prince Rupert Regional Hospital
-
Vancouver, British Columbia, Canada, V6H 3N1
- Children's & Women's Health Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Ste-Justine
-
Québec, Quebec, Canada, G1L3L5
- CHU de Québec - Université Laval
-
Sept-Îles, Quebec, Canada, G4R 0N9
- CIUSSS Côte-Nord
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Pregnant women 19 years or older wanting prenatal screening
- 10-13+6 wks determined by dating ultrasound or last menstrual period.
- Not intending to pursue self pay NIPT
Exclusion Criteria:
- Known fetal anomaly at the time of recruitment
- Multiple gestation
- Known twin demise
- Planned CVS or amnio for known genetic condition.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Screening
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Standard of care (2nd tier NIPS)
For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis). |
biochemical prenatal screening with or without nuchal translucency by US
Andre navne:
genomics based NIPS after a positive traditional prenatal screen
Andre navne:
amniocentesis or chorionic villi sampling (CVS) |
|
Eksperimentel: First-tier NIPS
For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis). |
amniocentesis or chorionic villi sampling (CVS) genomics based NIPS at first trimester
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gestational age at diagnosis
Tidsramme: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a positive NIPS result and that have been offered diagnostic testing |
Up to 24 weeks of gestational age
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gestational age at negative screening result
Tidsramme: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a negative screening result |
Up to 24 weeks of gestational age
|
|
Gestational age at positive screening result
Tidsramme: Up to 24 weeks of gestational age
|
gestational age at final result in the sub-set of participants that have received a positive screening result |
Up to 24 weeks of gestational age
|
|
proportion of women with no results
Tidsramme: Up to 24 weeks of gestational age
|
proportion of women with no NIPS result at first and second attempt |
Up to 24 weeks of gestational age
|
|
numbers of days for women with false positive result of screen to wait for result of definite test
Tidsramme: Up to 24 weeks of gestational age
|
Difference between gestational age (in days) at first positive prenatal screening result and final negative screening result |
Up to 24 weeks of gestational age
|
|
Change in PROMIS-29 Score
Tidsramme: At weeks of gestation 10-13, week 16 and week 22
|
The PROMIS-29 assesses seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to participate in social roles and activities. Each of the seven domains has four questions which are scored on a five-point Likert scale. The PROMIS-29 scales will be scored using a T-score metric method available at the Assessment Center website (http://assessmentcenter.net). A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Higher scores mean more of the specific scale's construct, which may indicate a desirable or an undesirable outcome. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation. |
At weeks of gestation 10-13, week 16 and week 22
|
|
Change in PROMIS Emotional Distress - Anxiety - Short Form 8a Score
Tidsramme: At weeks of gestation 10-13, 16 and 22
|
The PROMIS-Anxiety short form assesses anxiety with 8 questions. The form includes 8 items and uses a scale of 1-5 (1=Never, 2=Almost never, 3= Sometimes, 4=Often, 5=Almost always). The raw score is the sum of the points for each response. A higher than average raw score indicates higher than average anxiety. A higher score represents higher levels of anxiety. The assessment will be done at recruitment (10-13 weeks of gestation) and at week 16 and week 22 of gestation. |
At weeks of gestation 10-13, 16 and 22
|
|
Patient-Reported Experience Measure (PREM) - Score
Tidsramme: At 22 weeks of gestation
|
A 17-questions validated PREM questionnaire on pregnancy experience that measures three dimensions - type of prenatal care received and test results (seven questions), pregnancy visits (four questions (scales 1-5) and prenatal screening experience (six questions). A profile score by looking at frequencies of responses for each item will be used. |
At 22 weeks of gestation
|
|
gestational age at termination of pregnancy
Tidsramme: Up to 24 weeks of gestational age
|
Gestational age at termination of pregnancy for participants having volountary termination |
Up to 24 weeks of gestational age
|
|
percentage of women undergoing invasive diagnostic testing
Tidsramme: Up to 24 weeks of gestational age
|
see outcome title |
Up to 24 weeks of gestational age
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Sylvie Langlois, MD FRCPC, University of British Columbia
- Ledende efterforsker: Francois Rousseau, MD MSc FRCPC, CHU de Québec - Université Laval
Publikationer og nyttige links
Generelle publikationer
- Badeau M, Lindsay C, Blais J, Nshimyumukiza L, Takwoingi Y, Langlois S, Legare F, Giguere Y, Turgeon AF, Witteman W, Rousseau F. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database Syst Rev. 2017 Nov 10;11(11):CD011767. doi: 10.1002/14651858.CD011767.pub2.
- Dubeau A, El Balqui M, Talbot D, Rousseau F, Langlois S, Chen W, Audibert F, Bujold E, Forest JC, Dofara SG, Legare F. Validation of PREM-PS, a patient-reported experience instrument, in a randomized controlled trial of pregnant women undergoing prenatal screening. J Patient Rep Outcomes. 2026 Mar 7;10(1):59. doi: 10.1186/s41687-026-01020-5.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SIRUL 118984
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .